393 related articles for article (PubMed ID: 29507399)
1. Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy.
Oikonomou A; Khalvati F; Tyrrell PN; Haider MA; Tarique U; Jimenez-Juan L; Tjong MC; Poon I; Eilaghi A; Ehrlich L; Cheung P
Sci Rep; 2018 Mar; 8(1):4003. PubMed ID: 29507399
[TBL] [Abstract][Full Text] [Related]
2. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
[TBL] [Abstract][Full Text] [Related]
3. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
4. Prognositc significance of SUV
Dong M; Liu J; Sun X; Xing L
J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment
Dissaux G; Visvikis D; Da-Ano R; Pradier O; Chajon E; Barillot I; Duvergé L; Masson I; Abgral R; Santiago Ribeiro MJ; Devillers A; Pallardy A; Fleury V; Mahé MA; De Crevoisier R; Hatt M; Schick U
J Nucl Med; 2020 Jun; 61(6):814-820. PubMed ID: 31732678
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
[TBL] [Abstract][Full Text] [Related]
7. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy.
Li Q; Kim J; Balagurunathan Y; Qi J; Liu Y; Latifi K; Moros EG; Schabath MB; Ye Z; Gillies RJ; Dilling TJ
Radiat Oncol; 2017 Sep; 12(1):158. PubMed ID: 28946909
[TBL] [Abstract][Full Text] [Related]
8. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
[TBL] [Abstract][Full Text] [Related]
9. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
Tan D; Gill S; Loh N
Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
[TBL] [Abstract][Full Text] [Related]
10. A SUV
Ye L; Xu F; Shi S; Zeng Z; Jin X; Huang Y; Lu C; Gu J; Ge D; He J
Clin Transl Oncol; 2018 Aug; 20(8):1026-1034. PubMed ID: 29327241
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.
Takeda K; Takanami K; Shirata Y; Yamamoto T; Takahashi N; Ito K; Takase K; Jingu K
J Radiat Res; 2017 Nov; 58(6):862-869. PubMed ID: 29036692
[TBL] [Abstract][Full Text] [Related]
12. A PET/CT radiomics model for predicting distant metastasis in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy: a multicentric study.
Yu L; Zhang Z; Yi H; Wang J; Li J; Wang X; Bai H; Ge H; Zheng X; Ni J; Qi H; Guan Y; Xu W; Zhu Z; Xing L; Dekker A; Wee L; Traverso A; Ye Z; Yuan Z
Radiat Oncol; 2024 Jan; 19(1):10. PubMed ID: 38254106
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
Schonewolf CA; Verma V; Post CM; Berman AT; Frick MA; Vachani A; Lin C; Simone CB
Lung Cancer; 2018 Mar; 117():53-59. PubMed ID: 28800837
[TBL] [Abstract][Full Text] [Related]
14. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.
Reddy JP; Tang C; Shih T; Kim B; Kim C; Nguyen QN; Welsh J; Benveniste M; Zhang J; Liao Z; Gomez DR
Clin Lung Cancer; 2017 Mar; 18(2):141-148. PubMed ID: 27913215
[TBL] [Abstract][Full Text] [Related]
15. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
[TBL] [Abstract][Full Text] [Related]
16. Radiomics for prediction of radiation-induced lung injury and oncologic outcome after robotic stereotactic body radiotherapy of lung cancer: results from two independent institutions.
Bousabarah K; Blanck O; Temming S; Wilhelm ML; Hoevels M; Baus WW; Ruess D; Visser-Vandewalle V; Ruge MI; Treuer H; Kocher M
Radiat Oncol; 2021 Apr; 16(1):74. PubMed ID: 33863358
[TBL] [Abstract][Full Text] [Related]
17. Multicentric development and evaluation of [
Lucia F; Louis T; Cousin F; Bourbonne V; Visvikis D; Mievis C; Jansen N; Duysinx B; Le Pennec R; Nebbache M; Rehn M; Hamya M; Geier M; Salaun PY; Schick U; Hatt M; Coucke P; Hustinx R; Lovinfosse P
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1097-1108. PubMed ID: 37987783
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment
Satoh Y; Motosugi U; Saito A; Omiya Y; Onishi H
Technol Cancer Res Treat; 2018 Jan; 17():1533033818794934. PubMed ID: 30222060
[TBL] [Abstract][Full Text] [Related]
19. Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control.
Tyran M; Charrier N; Darreon J; Madroszyk A; Tallet A; Salem N
In Vivo; 2018; 32(1):121-124. PubMed ID: 29275308
[TBL] [Abstract][Full Text] [Related]
20. SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer.
Kwak YK; Park HH; Choi KH; Park EY; Sung SY; Lee SW; Hong JH; Lee HC; Yoo IR; Kim YS
Cancer Res Treat; 2020 Jan; 52(1):85-97. PubMed ID: 31122008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
